Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Mercy, one of the nation’s most highly integrated, multi-state health care systems, today announced a definitive agreement for Quest to acquire the outreach laboratory services business of Mercy in an all-cash asset transaction
| SECAUCUS, N.J., and ST. LOUIS, March 8, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Mercy, one of the nation’s most highly integrated, multi-state health care systems, today announced a definitive agreement for Quest to acquire the outreach laboratory services business of Mercy in an all-cash asset transaction. The aim of the transaction is to broaden access to innovative, quality and cost-effective laboratory services to deliver affordable patient care throughout the Midwest.
The Mercy outreach lab services business currently operates from 29 hospital laboratories and two independent clinic laboratories serving providers and patients in Arkansas, Kansas, Missouri and Oklahoma. Under the agreement, testing associated with outreach lab services will transition to the Quest Diagnostics full-service laboratory in Lenexa, Kansas, and a network of rapid response laboratories across the region. Mercy will continue to wholly own and operate its hospital labs for tests connected to inpatient and hospital-based outpatient care needs. Assuming the transaction’s completion, physicians and patients across the four states will benefit from access to Quest’s industry-leading and highly innovative test menu, a larger network of conveniently located patient service centers, broad health plan coverage and competitive pricing. “Mercy chose Quest to provide outreach lab testing because of its record of innovation and efficiency and our shared commitment to providing high-quality, convenient care that is accessible to all,” said Lynn Britton, president and CEO, Mercy. “This relationship gives our patients and providers more convenient locations for sample collection and a significantly lower cost of testing while maintaining the same high quality patients and providers need.” “As one of the country’s leading large health systems, Mercy is exiting the physician lab outreach business to sharpen its focus on providing high-quality, equitable care,” said Steve Rusckowski, Quest Diagnostics Chairman, CEO and President. “We look forward to working closely with Mercy to support their lab strategy. As pressures from the pandemic ease, and customer expectations and reimbursement pressures rise, we are talking to more and more top health systems about how Quest can help them enhance the effectiveness of their lab strategies.” Mercy selected Quest Diagnostics based on several factors, including Quest Diagnostics’ commitment to quality, innovation, cost efficiencies and patient care. Another factor was Mercy and Quest’s shared commitment to assisting underserved communities: In 2020, Quest Diagnostics, through its foundation, pledged to invest more than $100 million to address racial disparities in healthcare through its Quest for Health Equity initiative. The parties expect to complete the transaction in the second quarter of 2021, subject to customary regulatory approvals. Financial details of the transaction were not disclosed. About Mercy About Quest Diagnostics
SOURCE Quest Diagnostics | ||
Company Codes: NYSE:DGX |
View original content to download multimedia:
